Forte Biosciences (FBRX) Cash from Investing Activities (2016 - 2025)
Forte Biosciences (FBRX) reported Cash from Investing Activities of -$55000.0 for Q3 2025, down 100.15% quarter-over-quarter from $36.3 million in Q1 2025.
Forte Biosciences (FBRX) Cash from Investing Activities (2016 - 2025) Analysis & Trends
Forte Biosciences (FBRX) has 8 years of Cash from Investing Activities data on file, last reported at -$55000.0 in Q3 2025.
- Cash from Investing Activities for Q3 2025 came in at -$55000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was -$55000.0 (down 118.21% YoY), and the FY2025 annual result was $36.2 million, up 200.67% from the prior year.
- Cash from Investing Activities eased to -$55000.0 in Q3 2025 per FBRX's latest filing, from $36.3 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $36.3 million in Q1 2025 and troughed at -$36.0 million in Q4 2024.
- A 3-year average of $1.7 million and a median of -$11000.0 in 2023 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities sank 224818.75% in 2024, then soared 604916.67% in 2025.
- A 3-year view of Cash from Investing Activities shows it stood at -$16000.0 in 2023, then slumped by 224818.75% to -$36.0 million in 2024, then soared by 99.85% to -$55000.0 in 2025.
- Business Quant data shows FBRX's Cash from Investing Activities at -$55000.0 in Q3 2025, $36.3 million in Q1 2025, and -$36.0 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Forte Biosciences | 70.77 Mn | 12.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -55,000.00 |
| Sep 30, 2025 | -55,000.00 |
| Mar 31, 2025 | 36.29 Mn |
| Mar 31, 2025 | 36.29 Mn |
| Dec 31, 2024 | -35.99 Mn |
| Dec 31, 2024 | -35.99 Mn |
| Mar 31, 2024 | -6,000.00 |
| Mar 31, 2024 | -6,000.00 |
| Dec 31, 2023 | -16,000.00 |
| Dec 31, 2023 | -16,000.00 |
| Sep 30, 2023 | 10.03 Mn |
| Sep 30, 2023 | 10.03 Mn |
| Sep 30, 2020 | -1,000.00 |
| Sep 30, 2020 | -1,000.00 |
| Jun 30, 2020 | -9.14 Mn |
| Jun 30, 2020 | -9.14 Mn |
| Mar 31, 2020 | 12.72 Mn |
| Mar 31, 2020 | 12.72 Mn |
| Dec 31, 2019 | -89,000.00 |
| Dec 31, 2019 | -89,000.00 |